PeptiGrowth Inc.

Business

Solve challenges of conventional growth factors

Challenges of conventional growth factors

Currently, FBS and recombinant growth factors are used for cell culture. However, such products have some challenges such as variation in quality among production lots, contamination by biological impurities, low stability, and extremely high prices.

Growth Factor Alternative Peptide
Growth Factor Alternative Peptide

For the increased efficiencies and cost reduction in R&D and manufacturing of cell products.

PeptiGrowth is utilizing the proprietary technology of its shareholder PeptiDream to develop “Growth Factor Alternative Peptide” that performs equivalent functions to conventional growth factors. “Growth Factor Alternative Peptide” are manufactured solely through the use of chemical synthesis to solve many challenges of conventional growth factors.
By delivering products with consistent quality across manufacturing lots, experimental data repeatability is high and with better handling characteristics and easier contaminant management at a fair price, significant efficiency improvement and cost reduction in R&D and manufacturing activities for regenerative medicine and cell therapy can be achieved.

Comparison to conventional growth factors

Fetal bovine serum growth factor
Fetal bovine serum growth factor
Recombinant Growth Factor
Recombinant Growth Factor
Growth Factor Alternative Peptide
Growth Factor Alternative Peptide
Variation in quality among manufacturing lots
Inconsistent

Consistent

Consistent
Improved data reproducibility
Non-biological Origin
Biological Origin

Non-biological Origin

Non-biological Origin
Easy impurity management
Stability
Low

Low

High
Easy product handling
Price
High Price

Very High Price

Reasonable Price
Cost reductions

We will lead the world with technology and innovative idea

PeptiGrowth is targeting and conducting the development of numerous growth factors. Additionally, GMP grade is also available for clinical trials of regenerative medicine and cell therapy. We are committed to solving the challenges that face the pharmaceutical industry and promoting a wider acceptance of cell therapy and regenerative medicine.

We were established to develop numerous growth factor alternative peptides so that they would work with a variety of cell types

img-1
img-2
img-3
img-4
img-5
img-6
img-7
img-8
img-9
img-10

We will lead the world to open the future of regenerative medicine and cell therapy.